Seeking Alpha

FDA accepts Nabriva's refiled Contepo application; shares up 8% after hours

|About: Nabriva Therapeutics plc (NBRV)|By: , SA News Editor

The FDA accepts for review Nabriva Therapeutics' (NASDAQ:NBRV) resubmitted marketing application for Contepo (fosfomycin) for the treatment of complicated urinary tract infections. The agency's action date is June 19.

The company received a CRL last year citing deficiencies at one of its contract manufacturers.

Shares up 8% after hours.

Try Seeking Alpha PREMIUM for unlimited analysis on NBRV